Validation of multiparametric MRI with histopathology for prostate cancer
- Conditions
- histopathologyMRIprostate cancer10038597
- Registration Number
- NL-OMON40322
- Lead Sponsor
- ederlands Kanker Instituut
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 15
Inclusion Criteria
Patients with biopsy-proven prostate cancer who are scheduled for a prostatectomy
Exclusion Criteria
• Contra-indications for a MRI exam according to the standard protocol for the screening of patients with prostate cancer
• Treatment of prostate cancer prior to the MRI exams
• Prior hormonal therapy
• Prior trans-urethral resection (TURP)
• GFR < 30 ml/min/1,73 m²
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The robustness of multiparametric imaging for planning of dose painting<br /><br>radiotherapy of prostate cancer is investigated. The variation in the<br /><br>prediction of tumor probability is determined in a test-retest setting.</p><br>
- Secondary Outcome Measures
Name Time Method <p>• Determine the reproducibility of multi-parametric quantitative MRI<br /><br>• Determine whether there are differences in reproducibility of<br /><br>multi-parametric quantitative MRI between centers<br /><br>• Determine the impact of variations in predicted tumor probability on the<br /><br>planned treatment dose<br /><br>• Validate the predicted tumor probability with whole-mount section histology<br /><br>of prostatectomy specimen</p><br>